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Abstract
Atrial fibrillation, a common problem in patients with heart failure, is associated with increased
mortality and morbidity. Pharmacological as well as invasive management and the endpoints of such
management are complex. Recent randomized trials indicate that a rate-control strategy, along
with anticoagulation treatment with warfarin, when appropriate, has a similar outcome in terms of
mortality and morbidity as rhythm control, and could, therefore, be considered as the primary
management strategy for atrial fibrillation in patients with heart failure.
Introduction and context
Atrial fibrillation and heart failure are emerging and co-
existing cardiovascular disease epidemics of the new
millennium [1]. Both affect each other and both are
associated with substantial mortality and morbidity.
Atrial fibrillation, present in 10-40% of patients with
heart failure, is associated with adverse clinical con-
sequences, including excess risk of death, hemodynamic
decompensation, exacerbation of heart failure, impaired
functional capacity, and risk of stroke [1–7]. The adverse
impact of atrial fibrillation in heart failure has been
attributed to the presence of irregular and/or excessive
ventricular rates, lack of atrial contribution to ventricular
filling, and the toxicity of therapies prescribed to control
rate, to control rhythm, and to reduce the risk of stroke.
In addition to anticoagulation, rate control [drugs or
atrioventricular (AV) junctional ablation] is probably the
only option for permanent atrial fibrillation, but the
optimal strategy for managing paroxysmal and persistent
atrial fibrillation in heart failure remains uncertain.
Given adverse prognostic implications and postulated
hemodynamic consequences, aggressive re-establish-
ment and maintenance of sinus rhythm with antiar-
rhythmic drugs and/or ablation has been advocated, and
frequently attempted, in the hope of achieving better
outcomes [8]. On the other hand, interventions to
attempt to maintain sinus rhythm may be ineffective,
temporary, and potentially toxic.
Recent advances
Available data show no benefit for a routine rhythm-
control strategy for management of atrial fibrillation
[9–11] but only a small minority of the patients enrolled
had systolic dysfunction. A recent prospective, multi-
center, randomized clinical trial, termed the Atrial
Fibrillation and Congestive Heart Failure (AF-CHF)
trial [12], confirms this same finding in the heart failure
population. The AF-CHF trial randomized 1,376 patients
with paroxysmal or persistent atrial fibrillation, a left
ventricular ejection fraction < 35%, and New York Heart
Association (NYHA) functional class III or IV heart
failure, to a rate-control strategy (using beta-blockers
and/or digoxin with AV junctional ablation if drugs were
ineffective) or a rhythm-control approach (amiodarone
along with electrical cardioversion as needed). The
rhythm-control group was associated with a substantial
increase in sinus rhythm but no obvious benefit was seen
during the 37 ± 19-month follow-up. Death from
cardiovascular causes, adjusted for baseline differences,
was the same in both groups. Secondary outcomes,
including death from any cause, stroke, and worsening
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lizations were greater in the rhythm-control group.
It is unclear whether a better therapy to maintain sinus
rhythm would have had a better outcome. Given the
currently reported success rates of atrial fibrillation
ablation, it is unlikely that ablation would be better
than the rhythm-control strategy (that is, amiodarone)
used in the AF-CHF trial.
In regard to pharmacologic therapy to maintain sinus
rhythm, amiodarone appears to be the most potent [13].
Only amiodarone and dofetilide have been shown to
have a neutral effect on survival when compared to
placebo [4,14–17], but these drugs may have long-term
toxicity. Dronedarone, a congener of amiodarone (with
its multichannel-blocking abilities, but without its
iodine-related moiety), seemed appealing in this regard.
The recently reported Anti-arrhythmic Trial with Drone-
darone in Moderate to Severe Congestive Heart Failure
Evaluating Morbidity Decrease (ANDROMEDA), com-
pared dronedarone with placebo in atrial fibrillation
patients who had heart failure and a left ventricular
ejection fraction < 35% [18]. The study was terminated
prematurely after enrolling 627 patients (310 taking
dronedarone and 317 taking placebo) over a 7-month
period (median follow-up of 2 months) as mortality
was significantly increased in the dronedarone arm
(8.1versus3.8%intheplaceboarm).Thisexcessmortality
was predominantly due to deaths from worsening heart
failure and was greatest in patients with the most severe
left ventricular dysfunction. Treatment with dronedarone
was the most powerful predictor ofdeath after adjustment
for other risk factors. This study dealt a blow at efforts to
develop a safe and effective antiarrhythmic drug to use for
atrial fibrillation in heart failure.
Although previous studies indicate that atrial fibrillation
is independently associated with increased mortality in
heart failure, in reality, atrial fibrillation may simply be a
marker of poor prognosis, as these heart failure patients
may be more ill. Thus, the rhythm by itself may not need
treatment except to manage adverse consequences – that
is, exacerbation of heart failure and risk of thromboem-
bolism – in selected patients. Available evidence
supports this thesis.
Adjunctive therapies, including angiotensin-converting
enzyme inhibitors (ACEIs), angiotensin receptor block-
ers (ARBs), statins, and omega-3 fatty acids, may also
help prevent atrial fibrillation in heart failure patients.
Modulation of the renin-angiotensin system by ACEIs
has been shown to attenuate arrhythmogenic atrial
structural remodeling in experimental models of heart
failure [19]. A meta-analysis of randomized clinical trials
showed that use of both ACEIs and ARBs significantly
reduced (relative risk reduction = 44%) the incidence of
atrial fibrillation in patients with systolic heart failure
[20]. Both statins and omega-3 fatty acids have been
thought to have favorable effects on atrial structural
remodeling in heart failure [21,22], but the exact
mechanisms as well as the magnitude of their beneficial
effects remain unclear.
Implications for clinical practice
It is time to rethink the widely held belief that restoration
and maintenance of sinus rhythm using antiarrhythmics
and serial electrical cardioversions benefits patients with
systolic dysfunction and heart failure. A strategy aimed at
sinus rhythm does not improve cardiovascular and all-
cause mortality, risk of stroke, and worsening of heart
failure [12]. Instead, it can result in repeated cardiover-
sions, hospitalization from drug-related side effects, and
even increased mortality, as shown with the use of
dronedarone [18].
Whether invasive attempts at rhythm control, such as by
ablation, will improve outcomes, remains to be seen. At
present, rate control with appropriate anticoagulation
should be considered as the primary strategy to manage
atrial fibrillation in patients with heart failure. Beta-
blockers with or without digoxin should be first-linerate-
control agents but multiple drug combinations and even
AV junctional ablation may be needed [23]. In regard to
anticoagulation, no substitute exists for warfarin,
although direct thrombin inhibitors are being tested
[24]. Rhythm control should only be pursued in those
highly symptomatic heart failure patients who have
rapid uncontrolled atrial fibrillation that fails to respond
to standard rate-control therapy and for selected patients
who are shown to have worsening heart failure
symptoms and/or poor quality of life attributable to
atrial fibrillation, despite adequate rate control.
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